A

Agile Therapeutics Inc
F:0AL

Watchlist Manager
Agile Therapeutics Inc
F:0AL
Watchlist
Price: 1.11 EUR -1.77%
Market Cap: 9.3m EUR

Relative Value

0AL price has not been updated for more than 7 months. This may indicate that the stock has been delisted.
0AL doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of 0AL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0AL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

0AL Competitors Multiples
Agile Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Agile Therapeutics Inc
F:0AL
9.3m EUR 0.5 -1.4 -0.6 -0.6
US
Eli Lilly and Co
NYSE:LLY
977.5B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
519.4B USD 5.7 20.7 16.9 22
CH
Roche Holding AG
SIX:ROG
272.5B CHF 4.5 29.1 12.4 14.4
UK
AstraZeneca PLC
LSE:AZN
206.5B GBP 0 0.3 0 0
CH
Novartis AG
SIX:NOVN
219.3B CHF 4.9 19.1 15.1 19.6
US
Merck & Co Inc
NYSE:MRK
269.7B USD 4.2 14.2 10.1 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.4 13.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
144.7B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
A
Agile Therapeutics Inc
F:0AL
Average P/E: 21
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.1
29%
1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Agile Therapeutics Inc
F:0AL
Average EV/EBITDA: 45.5
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
16.9
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
CH
Novartis AG
SIX:NOVN
15.1
6%
2.5
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Agile Therapeutics Inc
F:0AL
Average EV/EBIT: 99.7
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
1.9
98%
0
US
Johnson & Johnson
NYSE:JNJ
22
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.4
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
0
23%
0
CH
Novartis AG
SIX:NOVN
19.6
12%
1.6
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5